4D Molecular Therapeutics Inc (FDMT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $14.96 (+1.91%), Market cap $0.48B, 52-week low–high $3.42 ~ $12.27.
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geograph
Financial statements, price targets, institutional (13F) holdings and related news for 4D Molecular Therapeutics Inc are updated in real time on BlackAll Trade.
4D Molecular Therapeutics Inc trades at $14.96 (+1.91%). Real-time quotes and charts are available on BlackAll Trade.
4D Molecular Therapeutics Inc has a market cap of about $0.48B.
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic